Intensity Therapeutics (INTS), with a ~$13M market cap, closed up nearly 395% Thursday after publishing phase 1/2 results on its candidate for metastatic or refractory cancers, INT230-6.
The asset works by diffusion of cytotoxic agents, cisplatin and vinblastine sulfate, using direct injection
